41 filings · most recent first
CYTK 8-K Filings
Cytokinetics Announces Public Offering Of Common Stock
Cytokinetics Releases Corporate Presentation With Key Updates
Cytokinetics Reports Strong Q1 2026 Performance With Myqorzo Launch And
Cytokinetics Launches Myqorzo For Obstructive Hcm Across Us China And Europe
Cytokinetics Receives Eu Approval For Myqorzo To Treat Obstructive Hypertrophic
Fda Approves Cytokinetics Myqorzo For Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Receives Positive Opinion For Myqorzo In Eu
Cytokinetics Appoints New Chief Legal And Administrative Officer
Cytokinetics Reports Third Quarter 2025 Financial Results
Cytokinetics Announces Issuance Of 750 Million Convertible Senior Notes
Cytokinetics Participates In Late Cycle Meeting With Fda For Aficamten Nda
Cytokinetics Announces Underwriters Exercise Of Option For Additional Share
Cytokinetics Completes Public Offering And Concurrent Private Placement
Cytokinetics Releases Updated Corporate Presentation
Cytokinetics Announces Financing Agreements And Asset Purchase
Cytokinetics Presents New Data On Aficamten At Esc Congress 2025
Cytokinetics Presents New Aficamten Data At Esc Congress 2025
Cytokinetics Announces Positive Results For Aficamten In Hcm Treatment
Cytokinetics Appoints James M Daly To Board Of Directors
Cytokinetics Reports Second Quarter 2025 Financial Results
Cytokinetics Incorporated Announces Results Of Annual Meeting Of Stockholders
Cytokinetics Announces Q1 2025 Financial Results And Business Update
Fda Extends Pdufa Action Date For Aficamten Nda
Cytokinetics Provides Regulatory Update On Aficamten Nda
Cytokinetics Announces Fourth Quarter 2024 Financial Results And Provides
Cytokinetics Appoints Robert E Landry To Board Of Directors
Cytokinetics Announces Departure Of Chief Accounting Officer
Cytokinetics Grants Exclusive License To Bayer For Aficamten In Japan
Board Member Resignation
Cytokinetics Appoints New Chief Legal Officer
Cytokinetics Reports Q2 2024 Financial Results And Updates Guidance
Cytokinetics Addresses Acquisition Rumors And Strategic Plans
Cytokinetics Board Director Resignation And Shareholder Approvals At 2024
Cytokinetics Announces Positive Primary Results For Aficamten In Obstructive Hcm
Cytokinetics Reports Q1 2024 Financial Results And Initiates Pediatric Hcm Trial
Cytokinetics Announces Enrollment Open For Cedarhcm Pediatric Clinical Trial
Cytokinetics Announces Successful Phase 1 Data For Ck586 In Hfpef
Cytokinetics Appoints New Cfo
Cytokinetics Announces Positive Foresthcm Data At Acc Scientific Session
Cytokinetics Reports Q4 2023 Financial Results And Key Clinical Updates
Cytokinetics Cfo Resigns Due To Personal Health Reasons